Novo Nordisk Wegovy - Search News

Ozempic, Wegovy face US Medicare price negotiations

Hosted on MSN · 1d

Novo Suffers Wegovy Trial Setback as US Plans to Cut Price

Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new trial, adding to growing threats to the Danish company’s early dominance in the surging market for new weight-loss treatments.

Novo's Ozempic, Wegovy picked for US Medicare price negotiations

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.

Ars Technica · 1d

Wegovy and Ozempic top list of 15 drugs up for next price negotiations

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of federal price negotiations, which are scheduled to begin this year, with resulting bargained prices going into effect in 2027.

High-dose Wegovy leads to substantial weight loss in trial

Hosted on MSN · 1d

Novo Nordisk’s Wegovy Achieves Weight-Loss of 20.7% at Higher Dose, Study Says

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side-effects.

High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with Zepbound.

Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP trial to evaluate the effect of increasing the maximum dose to 7.2 mg. The trial randomized 1,407 adults with obesity, but not diabetes, to receive either 7.2 mg or 2.4 mg of semaglutide or placebo.

13h

Is Novo Nordisk Stock a Buy?

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

1don MSN

These Stocks Are Moving the Most Today: Apple, Qorvo, Novo Nordisk, SLB, J.B. Hunt, Rivian, Cloudflare, and More

Stocks rallied sharply Friday and the S&P 500 was on pace for its best week since early November.These stocks were making ...

1d

LVMH Reclaims Title of Europe’s Most Valuable Stock From Novo

It’s taken LVMH nearly a year-and-a-half to regain its spot as Europe’s biggest stock from Novo Nordisk A/S.

1don MSN

Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

2d

Finally An Attractive Entry Point Into Novo Nordisk

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

5don MSN

Zealand Seeks to Usurp Wegovy, Zepbound With Obesity Drug

There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...

2don MSN

Novo Nordisk, other companies to meet Danish prime minister following Trump's Greenland threat

The CEO of obesity drug manufacturer Novo Nordisk and heads of other Danish companies were expected to discuss preparations ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results